Clinical area: Oncology Indication(s): Prostate cancer Clinical stage: Phase II Mechanism of action: PSMA Drug type: D Year of discovery – IP: 2018– IP4 Est. year of launch: 2027 Market size: 3 Freedom to operate: 1 Level of financing: 1 Development stage: 2 Description¹⁸F-AlF-PSMA-11 (also referred to as ¹⁸F-AlF-PSMA-HBED-CC or… Continue Reading…
Clinical area: Oncology Indication(s): NET Clinical stage: Phase II/III Mechanism of action: SSTR Drug type: D Year of discovery – IP: <2010 – IP2 Est. year of launch: >2025 Market size: 3 Freedom to operate: 1 Level of financing: 2 Development stage: 3 Description18F-AlF-NOTA-octreotide (also known as 18F-AlF-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide, 18F-IMP466, and… Continue Reading…
Clinical area: Oncology Indication(s): Angiogenesis Clinical stage: Phase I/II Mechanism of action: RGD Drug type: D Year of discovery – IP: <2013 – IP3 Est. year of launch: >2025 Market size: 3 Freedom to operate: 2 Level of financing: 1 Development stage: 2 Description ¹⁸F-Alfatide (also known as ¹⁸F-AlF-NOTA-PRGD2 or… Continue Reading…
Below is a list of radiopharmaceuticals that have been discontinued over the years. While this list is not exhaustive, it offers valuable insights into compounds that, despite strong support from the radiopharmaceutical industry, were eventually withdrawn from the market for a variety of reasons. These discontinuations often stemmed from factors… Continue Reading…
Description 223Ra-Radium Dichloride (Xofigo), also known as Radium-223 dichloride, BAY88-8223, or Xofigo® (formerly 223Ra-Alpharadin), is a radioactive salt developed by Algeta ASA. It targets cancers that commonly metastasize to the bone. Unlike earlier radiotherapeutics, which were limited to pain palliation, 223Ra has demonstrated a significant improvement in overall survival (OS)… Continue Reading…
Description 201Tl-Thallium Chloride, also known as 201Tl-Thallous Chloride, is a widely used radioactive salt. It plays a critical role in myocardial perfusion imaging (MPI), a diagnostic imaging technique that evaluates blood flow to the heart muscle. Clinical Applications 1. Myocardial Perfusion Imaging (MPI):201Tl-Thallium Chloride is a valuable tool for diagnosing… Continue Reading…
Description 188Re-Rhenium Colloidal Sulfide is a specialized radiopharmaceutical treatment utilized in isotopic radiation synovectomy for addressing conditions in large-sized joints. This therapy delivers localized radiation directly to the affected joint to alleviate symptoms associated with arthritis and other joint disorders. Clinical Applications 188Re-Rhenium Colloidal Sulfide serves as the 188Re analogue… Continue Reading…
Description 188Re-HDD/Lipiodol, also known as 188Re-4-hexadecyl-1,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol/Lipiodol or its acetylated variant 188Re-AHDD-Lipiodol, is a therapeutic agent that combines iodinated fatty acid ethyl esters derived from poppy seed oil (marketed as Lipiodol™) with a radioactive rhenium complex. The acetylated form, AHDD-Lipiodol, incorporates acetyl groups to stabilize the sulfhydryl components in its formulation.… Continue Reading…
Description 188Re-Rhenium Etidronate, also known by its various designations such as 186Re-HEDP, hydroxyethylidene diphosphonate, 186Re-Etidronate, 188Re-Hydroxyethanediphosphonate, and 188Re-REK-1, is a radiopharmaceutical agent with significant applications in medical treatments. It is commercially available in India through BRIT/BARC for radiosynovectomy procedures. This compound is also being actively developed as a therapeutic agent… Continue Reading…
Description186Re-Rhenium Colloidal Sulfide is a widely recognized therapeutic agent employed in isotopic radiation synovectomy for treating medium-sized joints. This generic formulation, designated as 186Re-Rhenium Colloidal Sulfide, is particularly effective in delivering localized radiotherapy to joints affected by various arthritic conditions. Clinical ApplicationsThis formulation is primarily indicated for patients with rheumatoid… Continue Reading…